## WST: West Pharmaceutical Services, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.5% below STRENGTH zone (3.0-6.0%); PEG 3.43 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($249.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. North Growth Management Ltd. Acquires 4,000 Shares of West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251208T120842 | Bullish | Relevance: 98%
-  North Growth Management Ltd. increased its stake in West Pharmaceutical Services, Inc. by 16% in the second quarter, acquiring an additional 4,000 shares, bringing its total holdings to 29,000 shares valued at approximately $6.36 million. This move follows West Pharmaceutical Services' strong Q earnings report, beating analyst estimates for both EPS and revenue, and the company has issued positive FY2025 guidance. Several other institutional investors have also adjusted their positions in the medical instruments supplier, which currently holds a "Moderate Buy" consensus rating among analysts with an average price target of $343.36.

**2. Invesco Ltd. Boosts Stake in West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251208T112026 | Somewhat-Bullish | Relevance: 98%
- Invesco Ltd. increased its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 1.1% in the second quarter, bringing its total ownership to 959,525 shares valued at $209.94 million. Several other institutional investors also adjusted their stakes in the medical instruments supplier. The article highlights the company's financial performance, stock trading activity, and recent analyst ratings.

**3. Arrowstreet Capital Limited Partnership Has $28.23 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251207T083009 | Bullish | Relevance: 98%
- Arrowstreet Capital Limited Partnership significantly increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, now holding 129,030 shares valued at approximately $28.23 million. The medical instruments supplier recently reported strong Q2 earnings, exceeding analyst expectations with an EPS of $1.96 and revenue of $804.6 million, and has issued positive FY2025 guidance. Institutional investors own 93.90% of the stock, which currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $343.36.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $285 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.01M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-6.5% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.4x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.43 signals overvaluation risk, limited margin of safety. Forward P/E 34.2x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.1B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.43 |
| Forward P/E | 34.2 |
| Current P/E | 37.5 |
| YoY Growth | 9.6% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 2.0% to -4.5% (-6.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.11x) but short-term weakness (below SMA20). RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.48% (CS: 10) | Weak |
| RSI_14 | 44.0 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 0.981x | Below |
| vs SMA50 | 0.972x | Below |
| vs SMA200 | 1.111x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $266.07
- **Stop Loss:** $249.27 (6.3% risk)
- **Target:** $282.87 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 17
- **Position Value:** $4,523.19
- **Portfolio %:** 4.52%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*